PlasmaTech Biopharmaceuticals Bolsters Scientific Advisory Board With Alpha-1 Expert Charlie Strange, M.D.

Print E-mail
Tuesday, 14 April 2015 10:21

DALLAS/NEW YORK CITY--PlasmaTech Biopharmaceuticals, Inc. PTBI, -2.09% a biopharmaceutical company advancing protein biologic therapies and viagra next day delivery oncology supportive care products, announced today it had appointed Charlie Strange, M.D. to its Scientific Advisory Board (SAB).

Read more...
 

AAA Reports 29.8% Sales Growth in 2014 While Continuing to Show Significant Clinical Progress Across Both Therapeutic and medexpressrx Diagnostic Platforms

Print E-mail
Thursday, 09 April 2015 19:28

NEW YORK/SAINT-GENIS-POUILLY, FRANCE--Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced its Q4 and full year 2014 financial results.

Read more...
 

PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval for MuGard in Korea

Print E-mail
Tuesday, 31 March 2015 10:56
DALLAS and NEW YORK--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: 128940) has received marketing approval in Korea from the purchase generic cialis online country's Ministry of Food and buy brand propecia online Drug Safety ("MFDS") and the buy cialis without prescription Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the buy propecia management of oral mucositis.
Read more...
 

Actinium Pharmaceuticals Opens Enrollment for the Fourth and propecia blogs Final Cohort in the Company’s Ongoing Phase I/II Trial in Acute Myeloid Leukemia

Print E-mail
Tuesday, 24 March 2015 07:56

NEW YORK, NY – March 24, 2015 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and viagra for sale treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and priligy review enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the Company’s investigational new drug Actimab-A at a higher activity level of 2.0 μCi/kg per dose. 

Read more...
 

Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort in the Company’s Ongoing Phase I/II Trial in Acute Myeloid Leukemia

Print E-mail
Tuesday, 24 March 2015 07:56

NEW YORK, NY – March 24, 2015 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the Company’s investigational new drug Actimab-A at a higher activity level of 2.0 μCi/kg per dose. 

Read more...
 

CEL-SCI REPORTS 2nd CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015 FOR ITS PHASE III HEAD AND buy real cialis NECK CANCER TRIAL

Print E-mail
Tuesday, 03 March 2015 11:56

Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) today announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).

Read more...
 

Pluristem and viagra pfizer Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation

Print E-mail
Tuesday, 03 March 2015 11:35

 HAIFA, ISRAEL, March 3, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation.

Read more...
 

Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015

Print E-mail
Tuesday, 24 February 2015 22:20

KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and brand viagra dermatology biopharmaceutical company (“Provectus”), announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.

Read more...
 

Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition

Print E-mail
Wednesday, 18 February 2015 19:39

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.

Read more...
 

Significant Findings in U.S. National Institutes of Health's Trial of Pluristem's PLX-R18 Cells for Treatment of Acute Radiation Syndrome

Print E-mail
Wednesday, 18 February 2015 08:50

HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today the positive results of a recently completed trial conducted by the U.S. National Institutes of Health (NIH) to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster.

Read more...
 
<< Start < Prev 1 3 4 5 > End >>

Page 1 of 5

Newsletter

BioMedReports GW Pharma gets Orphan Drug Designation From:   GW Pharmaceuticals PLC - ADR (NASDAQ:GWPH) has confirmed that ... http://t.co/RCFcEfJmPs
BioMedReports CEL-SCI is a Rare Value Opportunity in Cancer Immunotherapy Stocks http://t.co/pzSrwY1ohA
BioMedReports How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM: There's a new kind of incubator... http://t.co/ySkXvOvARL